BRAIN and NERVE－神経研究の進歩73巻7号

2021年07月発行

総説

CIDP治療の歩み—症状改善を目的とした治療から維持療法へ〜SCIgを中心に〜

著者： 神田隆¹ 飯島正博² 祖父江元³⁴

所属機関： ¹山口大学大学院医学系研究科臨床神経学講座 ²名古屋大学医学部附属病院先端医療開発部 ³名古屋大学大学院医学系研究科 ⁴愛知医科大学

ページ範囲：P.819 - P.828

文献概要

慢性炎症性脱髄性多発根ニューロパチー（CIDP）の治療に関する臨床研究は，2000年代前半までの初発・再発時における症状改善のための治療，2000年代後半以降の病勢進行の抑制を目的とする維持療法，さらに近年では個々の治療法の最適化へとコンセプトが移ってきた。 本総説ではCIDP治療に関わる過去の臨床研究を振り返り，これまでの変遷を概観する。そのうえでそれぞれの治療法の位置付けを明らかにし，課題と今後の治療開発の方向性について述べる。

参考文献

1）日本神経学会（監修）, 「慢性炎症性脱髄性多発根ニューロパチー, 多巣性運動ニューロパチー診療ガイドライン」作成委員会（編）: 慢性炎症性脱髄性多発根ニューロパチー, 多巣性運動ニューロパチー診療ガイドライン2013. 南江堂, 東京, 2013

2）Austin JH: Recurrent polyneuropathies and their corticosteroid treatment: with five-year observations of a placebo-controlled case treated with corticotrophin, cortisone, and prednisone. Brain 81: 157-192, 1958

3）Adams RD, Asbury AK, Michelsen JJ: Multifocal pseudohypertrophic neuropathy. Trans Am Neurol Assoc 90: 30-33, 1965

4）Hinman RC, Magee KR: Guillain-Barre syndrome with slow progressive onset and persistent elevation of spinal fluid protein. Ann Intern Med 67: 1007-1012, 1967

5）Thomas PK, Lascelles RG, Hallpike JF, Hewer RL: Recurrent and chronic relapsing Guillain-Barre polyneuritis. Brain 92: 589-606, 1967

6）Ashworth B, Smyth GE: Relapsing motor polyneuropathy. Acta Neurol Scand 45: 342-350, 1969

7）Matthews WB, Howell DA, Hughes RD: Relapsing corticosteroid-dependent polyneuritis. J Neurol Neurosurg Psychiatry 33: 330-337, 1970

8）Dolman CL, Allan BM: Relapsing hypertrophic neuritis. Arch Neurol 28: 351-353, 1973

9）Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, et al: Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 50: 621-637, 1975

10）Dyck PJ, O'Brien PC, Oviatt KF, Dinapoli RP, Daube JR, et al: Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 11: 136-141, 1982

11）van den Bergh PYK, Hadden RDM, Bouche P, Cornblath DR, Hahn A, et al: European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society, first revision. Eur J Neurol 17: 356-363, 2010

12）Dyck PJ, Daube J, O'Brien P, Pineda A, Low PA, et al: Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 314: 461-465, 1986

13）van Doorn PA, Brand A, Strengers PF, Meulstee J, Vermeulen M: High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology 40: 209-212, 1990

14）Vermeulen M, van Doorn PA, Brand A, Strengers PF, Jennekens FG, et al: Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 56: 36-39, 1993

15）Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, et al: A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 36: 838-845, 1994

16）Hahn AF, Bolton CF, Zochodne D, Feasby TE: Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, cross-over study. Brain 119: 1067-1077, 1996

17）久堀 保, 目崎高広, 梶 龍兒, 木村 淳, 濱口勝彦: NI-08（乾燥ポリエチレングリコール処理ヒト免疫グロブリン）の慢性炎症性脱髄性多発性神経炎における治療効果—第II相多施設共同試験. No To Shinkei 51: 127-135, 1999

18）Hughes R, Bensa S, Willison H, Van den Bergh P, Comi G, et al: Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 50: 195-201, 2001

19）Hughes RA, Donofrio P, Bril V, Dalakas MC, Deng C, et al: Intravenous immune globulin (10％ caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 7: 136-144, 2008

20）van Schaik IN, Eftimov F, van Doorn PA, Brusse E, van den Berg LH, et al: Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol 9: 245-253, 2010

21）Nobile-Orazio E, Cocito D, Jann S, Uncini A, Beghi E, et al: Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol 11: 493-502, 2012

22）Léger JM, De Bleecker JL, Sommer C, Robberecht W, Saarela M, et al: Efficacy and safety of Privigen (®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study). J Peripher Nerv Syst 18: 130-140, 2013

23）Kuwabara S, Mori M, Misawa S, Suzuki M, Nishiyama K, et al: Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial. J Neurol Neurosurg Psychiatry 88: 832-838, 2017

24）van Schaik IN, Bril V, van Geloven N, Hartung HP, Lewis RA, et al: Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 17: 35-46, 2018

25）Kuitwaard K, Fokkink WR, Brusse E, Vrancken AFJE, Eftimov F, et al: Protocol of a dose response trial of IV immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (DRIP study). J Peripher Nerv Syst 23: 5-10, 2018

26）Cornblath DR, Hartung HP, Katzberg HD, Merkies ISJ, van Doorn PA: A randomised, multi-centre phase Ⅲ study of 3 different doses of intravenous immunoglobulin 10％ in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): study design and protocol. J Peripher Nerv Syst 23: 108-114, 2018

27）飯島正博: CIDP—寛解維持療法. 末梢神経29: 2-8, 2018

28）Hughes RA, Mehndiratta MM, Rajabally YA: Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 11: CD002062, 2017［doi: 10.1002/14651858.CD002062.pub4］

29）Mehndiratta MM, Hughes RAC, Pritchard J: Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev: CD003906, 2015［doi: 10.1002/14651858.CD003906.pub4］

30）Oaklander AL, Lunn MP, Hughes RA, van Schaik IN, Frost C, et al: Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. Cochrane Database Syst Rev 1: CD010369, 2017［doi: 10.1002/14651858.CD010369.pub2］

31）Eftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN: Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev: CD001797, 2009［doi: 10.1002/14651858.CD001797.pub2］

32）Dalakas MC, Medscape: Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol 7: 507-517, 2011

33）Eftimov F, Vermeulen M, van Doorn PA, Brusse E, van Schaik IN, et al: Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment. Neurology 78: 1079-1084, 2012

34）Berger M, Jolles S, Orange JS, Sleasman JW: Bioavailability of IgG administered by the subcutaneous route. J Clin Immunol 33: 984-990, 2013

35）Lee DH, Linker RA, Paulus W, Schneider-Gold C, Chan A, et al: Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 37: 406-409, 2008

36）Cocito D, Serra G, Falcone Y, Paolasso I: The efficacy of subcutaneous immunoglobulin administration in chronic inflammatory demyelinating polyneuropathy responders to intravenous immunoglobulin. J Peripher Nerv Syst 16: 150-152, 2011

37）Markvardsen LH, Debost JC, Harbo T, Sindrup SH, Andersen H, et al: Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 20: 836-842, 2013

38）Mielke O, Bril V, Cornblath DR, Lawo JP, van Geloven N, et al: Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study. J Peripher Nerv Syst 24: 72-79, 2019

39）van Schaik IN, Mielke O, Bril V, van Geloven N, Hartung HP, et al: Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study. Neurol Neuroimmunol Neuroinflamm 6: e590, 2019［doi: 10.1212/NXI.0000000000000590］

40）Hartung HP, Mallick R, Bril V, Lewis RA, Sobue G, et al: Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study. Eur J Neurol 27: 196-203, 2020

41）飯島正博: 慢性炎症性脱髄性多発根ニューロパチー（CIDP）. 神経治療33: 168-171, 2016

42）Lunn MP, Ellis L, Hadden RD, Rajabally YA, Winer JB, et al: A proposed dosing algorithm for the individualized dosing of human immunoglobulin in chronic inflammatory neuropathies. J Peripher Nerv Syst 21: 33-37, 2016

43）Berger M, McCallus DE, Lin CS: Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies. J Peripher Nerv Syst 18: 275-296, 2013

44）Berger M: Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol 112: 1-7, 2004

45）Kuwabara S, Isose S, Mori M, Mitsuma S, Sawai S, et al: Different electrophysiological profiles and treatment response in ‘typical’ and ‘atypical’ chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 86: 1054-1059, 2015

46）Miura Y, Devaux JJ, Fukami Y, Manso C, Belghazi M, et al: Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxia. Brain 138: 1484-1491, 2015

47）Devaux JJ, Miura Y, Fukami Y, Inoue T, Manso C, et al: Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy. Neurology 86: 800-807, 2016